MedTrace Logo

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations

NCT03159572 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 996

Last updated 2024-11-21

No results posted yet for this study

Summary

To investigate the frequency and clinical significance of Homologous Recombination Deficiency (HRD) in Japanese patients with ovarian cancer (including Fallopian tube cancer and primary peritoneal cancer).

Conditions

Sponsors & Collaborators

  • Department of Obstetrics and Gynecology, School of Medicine, Niigata University

    collaborator UNKNOWN

  • Japanese Gynecologic Oncology Group

    collaborator OTHER

  • Tohoku Medical Megabank Organization(ToMMo)

    collaborator UNKNOWN

  • Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

    lead OTHER

Principal Investigators

  • Takayuki Enomoto, MD, Ph.D · Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-28
Primary Completion
2022-02-16
Completion
2022-02-16

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03159572 on ClinicalTrials.gov